MRI helps predict survival in rectal cancer

Share this content:

Using magnetic resonance imaging (MRI) to assess response to neoadjuvant chemotherapy or radiation may predict survival among persons with advanced rectal cancer.

In a prospective cohort study of 111 persons with locally advanced rectal cancer, researchers used MRI to measure tumor regression grade (assessing how much a tumor shrank) after patients underwent preoperative radiotherapy or chemoradiation. They also evaluated circumferential resection margin (CRM)—indicating the remaining cancer at the tumor edges after treatment, or predicted to remain after surgery. The study participants were deemed to be either “good” or “poor” responders to therapy based on MRI.

Five-year survival for poor response as determined by MRI assessments of tumor regression grade was 27%, compared with 72% for good responders. Disease-free survival was 64% for good responders vs 31% for poor responders. In addition, local recurrence rates at 5 years was 28% for those patients for whom there was MRI-predicted CRM involvement, compared with 12% for patients with predicted cancer-free tumor margins.

In their report for Journal of Clinical Oncology, investigators Gina Brown, MBBS, MD, of the radiology department at the Royal Marsden Hospital NHS Trust in Sutton, United Kingdom, and colleagues concluded that MRI assessment of tumor regression grade and CRM are imaging markers that can predict survival outcomes for good and poor responders, and that these markers provide an opportunity for the care team to offer additional treatment options before planning definitive surgery.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs